Hutchison China MediTech Says Fruquintinib Increased Median Survival 41%
publication date: Jun 2, 2017
Hutchison China MediTech (Chi-Med) reported positive survival data for its lead drug, fruquintinib. In a pivotal Phase III China trial, fruquintinib increased median survival in 416 colorectal cancer patients from 6.6 months to 9.3 months, a 41% improvement. Chi-Med released the data in conjunction with the current ASCO meeting in Chicago. In March, the company announced the trial was successful, but did not release details. Chi-Med, which partnered China development of fruquintinib with Lilly, plans to file an NDA with the CFDA for the drug. More details....
Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.